NASDAQ$IRWD
Ironwood Pharmaceuticals Inc. · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported strong second-quarter results and raised full-year guidance.
Ironwood Pharmaceuticals reported a strong second quarter in 2021, with U.S. LINZESS net sales increasing by 18% year-over-year to $259 million and total revenue increasing by 16% year-over-year to $104 million. The company's GAAP net income was $391 million, which included a $338 million non-recurring income tax benefit. Ironwood ended the quarter with $493 million in cash and cash equivalents and raised its full-year 2021 financial guidance.
- U.S. LINZESS net sales of $259 million, an increase of 18% year-over-year
- Total revenue of $104 million, an increase of 16% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $100 million
- GAAP net income of $391 million, includes a $338 million non-recurring income tax benefit related to the release of the valuation allowance against the majority of the company’s deferred tax assets
- Adjusted EBITDA of $65 million; ended Q2 2021 with $493 million in cash and cash equivalents
Headline financials
Revenue & EPS history
Ironwood Pharmaceuticals · Revenue · Quarterly
$104M
Revenue by segment
Ironwood Pharmaceuticals · $71M total across 1 segment · Q1 2020
- LINZESS Collaboration$71M—100.0%
Forward guidance
Ironwood is raising its 2021 financial guidance due to the growth in U.S. LINZESS prescription demand.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-1.0%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-1.2%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+32.8%
Q3 2025
Best reaction
-29.5%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -13.9% | -15.5% | -31.5% | |
| Q4 2025 | -11.4% | -5.8% | -19.3% | |
| Q3 2025 | +32.8% | +63.5% | +92.2% | |
| Q1 2025 | -4.4% | +0.0% | +5.1% | |
| Q4 2024 | -5.3% | -12.9% | -17.5% | |
| Q3 2024 | -1.6% | -12.9% | -31.9% | |
| Q2 2024 | -29.5% | -25.3% | -25.0% | |
| Q1 2024 | -13.8% | -18.3% | -21.8% | |
| Q4 2023 | -5.6% | -4.0% | -41.6% | |
| Q3 2023 | +5.5% | +5.6% | +13.5% | |
| Q2 2023 | -15.3% | -11.3% | -24.2% | |
| Q1 2023 | +1.5% | -2.4% | +4.9% | |
| Q4 2022 | +5.8% | +3.9% | -7.4% | |
| Q3 2022 | +3.7% | +6.8% | +11.9% | |
| Q2 2022 | +5.9% | +5.6% | -2.9% | |
| Q1 2022 | -3.0% | -8.4% | -9.0% | |
| Q4 2021 | -2.5% | -1.2% | +13.5% | |
| Q3 2021 | +0.4% | -1.2% | -14.6% | |
| Q2 2021 | +3.2% | +4.3% | -1.5% | |
| Q1 2021 | +1.3% | +1.5% | +9.3% | |
| Q4 2020 | -7.0% | -6.6% | +12.3% | |
| Q3 2020 | +4.0% | +12.4% | +16.8% | |
| Q2 2020 | +5.8% | +3.0% | +1.5% | |
| Q1 2020 | -3.2% | +2.5% | -5.3% | |
| Q4 2019 | -3.2% | -2.9% | -18.3% | |
| Q3 2019 | +10.0% | +15.9% | +27.5% | |
| Q2 2019 | +2.6% | -0.8% | -10.0% | |
| Q1 2019 | -9.9% | -12.3% | -7.2% | |
| Q4 2018 | +5.4% | +15.1% | +3.1% | |
| Q3 2018 | -15.6% | -15.9% | -10.3% | |
| Q2 2018 | -1.1% | -1.9% | -1.1% | |
| Q1 2018 | +4.4% | +2.6% | +2.5% | |
| Q4 2017 | +6.0% | +2.4% | +6.0% | |
| Q3 2017 | +6.8% | +1.8% | +16.6% | |
| Q2 2017 | -12.8% | -15.5% | -9.0% | |
| Q1 2017 | +5.2% | +12.9% | +10.5% | |
| Q4 2016 | -1.6% | -4.2% | +0.1% | |
| Q3 2016 | +7.2% | +15.2% | +22.5% | |
| Q2 2016 | -6.0% | -7.7% | -6.9% | |
| Q1 2016 | +9.3% | — | — | |
| Q4 2015 | +3.4% | — | — | |
| Q3 2015 | -1.2% | — | — | |
| Q2 2015 | +2.4% | — | — | |
| Q1 2015 | -0.1% | — | — | |
| Q4 2014 | -3.1% | — | — | |
| Q3 2014 | -0.9% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | +8.4% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | -4.0% | — | — | |
| Q2 2013 | +4.2% | — | — | |
| Q1 2013 | -8.9% | — | — | |
| Q4 2012 | -7.7% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | -3.8% | — | — | |
| Q1 2011 | -0.5% | — | — | |
| Q1 2012 | -3.5% | — | — | |
| Q4 2011 | -3.4% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q3 2011 | -13.6% | — | — | |
| Q2 2010 | +3.3% | — | — | |
| Q4 2010 | +0.1% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q1 2010 | -3.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro